Last reviewed · How we verify
HS-10296
HS-10296 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
HS-10296 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors, Urothelial carcinoma with FGFR alterations.
At a glance
| Generic name | HS-10296 |
|---|---|
| Also known as | Investigational Product |
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HS-10296 targets FGFR kinase activity to inhibit downstream proliferation and survival pathways in tumors with FGFR alterations. By selectively blocking FGFR signaling, the drug aims to suppress tumor growth in cancers driven by FGFR mutations, fusions, or amplifications.
Approved indications
- FGFR-altered solid tumors
- Urothelial carcinoma with FGFR alterations
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
- Stomatitis
Key clinical trials
- A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer (PHASE1)
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (PHASE2, PHASE3)
- A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC (PHASE1)
- PLATFORM Study of Precision Medicine for Rare Tumors (PHASE2)
- Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (PHASE2)
- Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations (PHASE3)
- Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations (PHASE3)
- Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10296 CI brief — competitive landscape report
- HS-10296 updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI